Skip to main content

Table 2 Outcome according to antiviral treatment

From: Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study

 

No antiviral

Lopinavir ritonavir

Hydroxychloroquine

Othera

Pb value

N = 85

N = 57

N = 220

N = 53

Ventilatory mode at day 14, n (%)

     

 Death

    

0.32

 Controlled mode or under VV-

15 (18)

12 (21)

58 (27)

9 (17)

 

ECMO

27 (32)

20 (35)

72 (33)

22 (42)

 Pressure support

16 (19)

12 (21)

45 (21)

14 (26)

 Extubated

27 (32)

13 (23)

44 (20)

8 (15)

Alive at day 28, n (%)

62 (73)

35 (61)

140 (64)

38 (72)

0.30

VFD at day 28, median [IQR]

5 [0–15]

0 [0–11]

0 [0–12]

0 [0–9]

0.03

N = 80/49/197/7/43

Acute kidney injury, n (%)

 No

38 (45)

17 (30)

106 (48)

22 (42)

0.002

 Yes without RRT

33 (39)

18 (32)

72 (33)

26 (49)

 

 Yes with RRT

14 (17)

22 (39)

41 (19)

5 (9)

 

Peak of creatinine, median [IQR]

115 [84–209]

198 [95–432]

122 [80–316]

145 [88–245]

0.05

N = 84/52/218/53

Acute cardiac injury, n (%)

8 (9)

6 (10)

37 (17)

4 (8)

0.14

Pulmonary embolism, n (%)

11 (13)

6 (11)

32 (15)

10 (19)

0.78

Deep venous thrombosis, n (%)

7 (8)

8 (14)

20 (9)

4 (8)

0.62

ICU survival, n (%)

56 (67)

27 (51)

123 (57)

34 (64)

0.22

N = 406

  1. a Other including HCQ + L/R N = 32; HCQ + REM N = 10; REM N = 11
  2. b P value was calculated using Chi-2, ANOVA, Kruskal–Wallis as appropriate
  3. RRT renal replacement therapy, VFD ventilator-free days, VV-ECMO veno-venous extracorporeal membrane oxygenation